0
     

Report Added
Report already added
U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers)- Forecast to 2029

The U.S. RWE solutions market is expected to grow at a CAGR of 13.1% from 2022 to 2029 to reach $2.22 billion by 2029

Following a thorough secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities
Growing incidence of chronic & infectious diseases, delays in drug development and the subsequent increase in development costs, rising focus towards personalized healthcare, a shift from volume to value-based care, and rapidly growing big data in healthcare are the key factors driving steady growth in the U.S. RWE solutions market. Further, significant opportunities for existing market players and new entrants are provided by rising focus on end-to-end RWE services, and rising adoption of wearable devices and AI in RWE

Based on component, in 2022, the datasets segment is expected to command the largest share in the market. Real-world data (RWD) are derived from various sources associated with outcomes in a heterogeneous patient population in real-world settings. Datasets are present in a secondary format on which retrospective studies are conducted to generate real-world evidence. This real-world evidence provides meaningful insights into unmet needs and the clinical and economic impacts on patients and healthcare systems. It also determines the outcomes based on much larger data samples, reduces costs, and improves the efficiency of clinical trials.

Based on application, the drug development & approvals segment is expected to show the fastest growth rate in the forecast period. Factors attributing towards the growth of this segment are increasing demand for real-world data and real-world evidence to accelerate drug discovery and development, and increasing investments by biopharmaceutical companies in R&D.
In the field of drug development, quality-of-life metrics, and Patient-Reported Outcome Measures (PROMs) are now becoming common elements in clinical trials. The evidence generated from real-world data is regularly utilized to inform aspects of drug development. The role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs.

Based on end user, the pharmaceutical & medical device companies segment is expected to show the fastest growth rate in the forecast period. The growth of this segment is primarily attributed to the increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.
The cost of developing a new drug was more than ~USD 2,600 million in 2020 compared to USD 802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face.

The key companies operating in the U.S. RWE solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA HOLDINGS INC. (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).

Scope of the Report
U.S. RWE Solutions Market, by Component
•Datasets
•Disparate Datasets
•EMR/EHR/Clinical Data
•Claims & Billing Data
•Pharmacy Data
•Product/Disease Registries Data
•Other Disparate Datasets
•Integrated Datasets
•Consulting and Analytics
(Note – Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)
U.S. RWE Solutions Market, by Application
•Market Access & Reimbursement/Coverage Decisions
•Drug Development & Approvals
•Oncology
•Neurology
•Immunology
•Cardiovascular Diseases
•Other Therapeutic Areas
•Post Market Surveillance
•Medical Device Development & Approvals
•Clinical and Regulatory Decision-Making
(Note – Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases)
U.S. RWE Solutions Market, by End User
•Pharmaceutical, Biotechnology, and Medical Device Companies
•Healthcare Payers
•Healthcare Providers
•Other End Users
(Note – Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)
Table of Contents

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency

2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study

3. Executive Summary

4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Growing Burden of Chronic and Infectious Diseases
4.2.2. Rising Focus Towards Personalized Healthcare
4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
4.2.4. Shift Towards Value-Based Care
4.2.5. Rapidly Growing Big Data in Healthcare
4.3. Restraints
4.3.1. Reluctance to Rely on Real-World Studies
4.4. Opportunities
4.4.1. Rising Focus on End-to-End RWE Services
4.4.2. Rising Adoption of Wearable Devices and Artificial Intelligence in RWE
4.5. Challenges
4.5.1. Lack of Standardized Methodologies to Develop RWE
4.6. Key Market Trends
4.6.1. Growing Adoption of RWE in Drug Development and Commercialization
4.6.2. Rising Number of Consolidations
4.6.3. Improved Patient Outcomes and Value Creation from Real-World Evidence
4.7. Impact Assessment of COVID-19 on the U.S. RWE Solutions Market

5. Regulatory Analysis – U.S. Real-World Evidence (RWE) Solutions Market

6. Pricing Models (EMR/Genomic/Integrated Datasets)
6.1. Introduction
6.2. Pay Per Patient Record (Volume-Based Pricing)
6.3. Pay Per Usage (Value-Based Pricing)
6.4. Annual Subscription

7. U.S. Real-World Evidence Solutions Market, by Component
7.1. Introduction
7.2. Datasets
7.2.1. Disparate Datasets
7.2.1.1. EMR/EHR/Clinical Data
7.2.1.2. Claims & Billing Data
7.2.1.3. Pharmacy Data
7.2.1.4. Product/Disease Registries Data
7.2.1.5. Other Disparate Datasets
7.2.2. Integrated Datasets
7.3. Consulting & Analytics

8. U.S. Real-World Evidence Solutions Market, by Application
8.1. Introduction
8.2. Market Access & Reimbursement/Coverage Decisions
8.3. Drug Development & Approvals
8.3.1. Oncology
8.3.2. Neurology
8.3.3. Immunology
8.3.4. Cardiovascular Diseases
8.3.5. Other Therapeutic Areas
8.4. Medical Device Development & Approvals
8.5. Post-Market Surveillance
8.6. Other Applications

9. U.S. Real-World Evidence Solutions Market, by End User
9.1. Introduction
9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
9.3. Healthcare Payers
9.4. Healthcare Providers
9.5. Other End Users

10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2020)
10.4.1. IQVIA Holdings, Inc. (U.S.)
10.4.2. ICON plc (Ireland)
10.4.3. PPD, Inc. (U.S.)

11. Company Profiles (Business Overview, Financial Overview, Solution Portfolio, Strategic Developments)
11.1. Anthem, Inc.
11.2. Clinigen Group plc.
11.3. Cognizant Technology Solutions Corporation
11.4. ICON plc
11.5. IQVIA HOLDINGS INC.
11.6. Oracle Corporation
11.7. PAREXEL International Corporation
11.8. PerkinElmer, Inc.
11.9. PPD, Inc.
11.10. SAS Institute Inc.
11.11. UnitedHealth Group Incorporated
11.12. Flatiron Health, Inc.

List of Tables

Table 1 U.S. Real-World Evidence Solutions Market Drivers: Impact Analysis (2022-2029)
Table 2 Total Per-Study Cost (In Usd Million), by Phase and Therapeutic Area
Table 3 Sources of Healthcare Data
Table 4 U.S. Real-World Evidence Solutions Market Restraints: Impact Analysis (2022-2029)
Table 5 Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
Table 6 U.S. Real-World Evidence Solutions Market Size, by Component, 2012–2029 (USD Million)
Table 7 U.S. Real-World Evidence Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 8 U.S. RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 9 U.S. Real-World Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 10 U.S. RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 11 Estimated Number of New Cancer Cases in the U.S. (2019–2023)
Table 12 Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
Table 13 Other Therapeutic Areas: Drugs in the R&D Pipeline
Table 14 U.S. RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 15 Recent Developments, by Company, 2018–2022

Report Title: U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Venom Based Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Animal Type (Snake, Spider, Bee, Others), By Source (Whole Venom, Synthetic, Recombinant, Others), By Therapeutic Area (Hypertension, Cardiovascular Diseases, Neurological Disorders, Pain Management & Arthritis, Others), By Company and By Region

Venom Based Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Animal Type (Snake, Spider, Bee, Others), By Source (Whole Venom, Synthetic, Recombinant, Others), By Therapeutic Area (Hypertension, Cardiovascular Diseases, Neurological Disorders, Pain Management & Arthritis, Others), By Company and By Region

Phage Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Bacteria Type (Salmonella, Bacteriophage, Streptococcus, E.Coli, Others), By Product (Oral Consumption, External Consumption, Surgical Treatment), By Application (Human Medicines, Veterinary Sciences, Food & Beverage, Others), and By Region

Phage Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Bacteria Type (Salmonella, Bacteriophage, Streptococcus, E.Coli, Others), By Product (Oral Consumption, External Consumption, Surgical Treatment), By Application (Human Medicines, Veterinary Sciences, Food & Beverage, Others), and By Region

Natural Killer Cells Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Type (Natural Killer Cell Therapies v/s Natural Killer Cell Directed Antibodies), By Application (Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, Others), By End User (Hospitals & Clinics, Academic & Research Institutions, Others), By Region

Natural Killer Cells Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Type (Natural Killer Cell Therapies v/s Natural Killer Cell Directed Antibodies), By Application (Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, Others), By End User (Hospitals & Clinics, Academic & Research Institutions, Others), By Region

Medication Reminder Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Type (Mobile Phone Reminders, In-Home Electronic Devices, Portable Reminder Devices), By End User (Homecare, Hospitals & Clinics, Others), By Company and By Region

Medication Reminder Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type (Mobile Phone Reminders, In-Home Electronic Devices, Portable Reminder Devices), By End User (Homecare, Hospitals & Clinics, Others), By Company and By Region

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Valence (Bivalent, Quadrivalent, Nonvalent, Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others), By Company and By Region

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Valence (Bivalent, Quadrivalent, Nonvalent, Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others), By Company and By Region

Hand, Foot, and Mouth Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Drug Type (Pain Relievers, Non-Steroidal Anti-inflammatory Drugs, Nucleoside Analogue Antivirals), By Route of Administration (Topical, Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Company, and By Region

Hand, Foot, and Mouth Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Drug Type (Pain Relievers, Non-Steroidal Anti-inflammatory Drugs, Nucleoside Analogue Antivirals), By Route of Administration (Topical, Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Company, and By Region